Nektar Therapeutics NKTR

NAS: NKTR | ISIN: US6402681083   12/09/2025
48,68 USD (+3,14%)
(+3,14%)   12/09/2025

9 september 2025 · Nektar Announces REZOLVE-AD Phase 2b Results for Rezpegaldesleukin Selected for Late-Breaker Oral Presentation at EADV 2025 · Persbericht

4 september 2025 · Nektar Therapeutics to Participate in Two Investor Conferences in September · Persbericht

7 augustus 2025 · Nektar Therapeutics Reports Second Quarter 2025 Financial Results · Persbericht

1 augustus 2025 · Nektar to Announce Financial Results for the Second Quarter on Thursday, August 7, 2025, After Close of U.S.-Based Financial Markets · Persbericht

29 juli 2025 · Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Severe-to-Very Severe Alopecia Areata · Persbericht

2 juli 2025 · Nektar Therapeutics Announces Closing of $115 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares · Persbericht

1 juli 2025 · Nektar Therapeutics Announces Pricing of $100 Million Public Offering · Persbericht

30 juni 2025 · Nektar Therapeutics Announces Proposed Public Offering · Persbericht

24 juni 2025 · REZOLVE-AD Phase 2b Study of Rezpegaldesleukin Meets Primary and Key Secondary Endpoints in Patients with Moderate-to-Severe Atopic Dermatitis · Persbericht

23 juni 2025 · Nektar to Announce Top-line Data from the 16-Week Induction Period in REZOLVE-AD Phase 2b Study of Rezpegaldesleukin, a Regulatory T-cell Proliferator, in Atopic Dermatitis on June 24, 2025 · Persbericht

13 mei 2025 · Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference · Persbericht

8 mei 2025 · Nektar Therapeutics Reports First Quarter 2025 Financial Results · Persbericht

2 mei 2025 · Nektar to Announce Financial Results for the First Quarter on Thursday, May 8, 2025, After Close of U.S.-Based Financial Markets · Persbericht

20 maart 2025 · Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference · Persbericht

12 maart 2025 · Nektar Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results · Persbericht

6 maart 2025 · Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2024 on Wednesday, March 12, 2025, After Close of U.S.-Based Financial Markets · Persbericht

3 september 2024 · Nektar Management to Present at Upcoming Investor Conferences · Persbericht

8 augustus 2024 · Nektar Therapeutics Reports Second Quarter 2024 Financial Results · Persbericht

2 augustus 2024 · Nektar to Announce Financial Results for the Second Quarter 2024 on Thursday, August 8, 2024, After Close of U.S.-Based Financial Markets · Persbericht

12 juni 2024 · Nektar Therapeutics Presents First Preclinical Data on NKTR-0165, a TNFR2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at EULAR 2024 · Persbericht

Mijn selecties